Annals

Special Issue: Myasthenia Gravis and Related Disorders II

Edited by

Ann NY Acad Sci editorial staff

Explore the Table of Contents
Special Issue: Myasthenia Gravis and Related Disorders II (vol 1413)

Published: February 2018

Volume 1413

Published since 1824, Annals of the New York Academy of Sciences is the Academy’s premier scientific publication.

Learn More

COMMENTARY

Clinical trials for myasthenia gravis: a historical perspective

Henry J. Kaminski, Eman Alnosair, Rami M. Algahtani

 

CONCISE REVIEWS

Toll‐like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?

Paola Cavalcante, Claudia Barzago, Fulvio Baggi, Carlo Antozzi, Lorenzo Maggi, Renato Mantegazza, Pia Bernasconi

The unfolding landscape of the congenital myasthenic syndromes

Andrew G. Engel, Xin‐Ming Shen, Duygu Selcen

Rationale for the clinical guidelines for myasthenia gravis in Japan

Hiroyuki Murai, Kimiaki Utsugisawa, Yuriko Nagane, Shigeaki Suzuki, Tomihiro Imai, Masakatsu Motomura

Rituximab in myasthenia gravis: a “to be or not to be” inhibitor of T cell function

Mariapaola Marino, Emanuela Bartoccioni, Paolo Emilio Alboini, Amelia Evoli

Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?

Elena Rinaldi, Alessandra Consonni, Elena Guidesi, Marina Elli, Renato Mantegazza, Fulvio Baggi

Pathophysiological mechanisms of autoimmunity

Muriel Sudres, Julien Verdier, Frédérique Truffault, Rozen Le Panse, Sonia Berrih‐Aknin

Comparative effectiveness clinical trials to advance treatment of myasthenia gravis

Jeffrey T. Guptill, Shruti Raja, Donald B. Sanders, Pushpa Narayanaswami

REVIEWS

Acetylcholine receptor–specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis

Jie Luo, Jon Lindstrom

Challenging the current model of early‐onset myasthenia gravis pathogenesis in the light of the MGTX trial and histological heterogeneity of thymectomy specimens

Cleo‐Aron Weis, Berthold Schalke, Philipp Ströbel, Alexander Marx

IgG4‐mediated autoimmune diseases: a niche of antibody‐mediated disorders

Maartje G. Huijbers, Jaap J. Plomp, Silvère M. van der Maarel, Jan J. Verschuuren

Congenital myasthenic syndromes with acetylcholinesterase deficiency, the pathophysiological mechanisms

Claire Legay

Passive transfer models of myasthenia gravis with muscle‐specific kinase antibodies

Jan J.G.M. Verschuuren, Jaap J. Plomp, Steve J. Burden, Wei Zhang, Yvonne E. Fillié‐Grijpma, Inge E. Stienstra‐van Es, Erik H. Niks, Mario Losen, Silvère M. van der Maarel, Maartje G. Huijbers

A presynaptic congenital myasthenic syndrome attributed to a homozygous sequence variant in LAMA5

Ricardo A. Maselli, Juan Arredondo, Jessica Vázquez, Jessica X. Chong, Michael J. Bamshad, Deborah A. Nickerson, Marian Lara, Fiona Ng, Victoria Lee Lo, Peter Pytel, et al

Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis

Min Yan, Guang‐Lin Xing, Wen‐Cheng Xiong, Lin Mei

Acetylcholine receptor antibody–mediated animal models of myasthenia gravis and the role of complement

Linda L. Kusner, Manjistha Sengupta, Henry J. Kaminski

Serological and experimental studies in different forms of myasthenia gravis

Angela Vincent, Saif Huda, Michelangelo Cao, Hakan Cetin, Inga Koneczny, Pedro Rodriguez‐Cruz, Leslie Jacobson, Stuart Viegas, Saiju Jacob, Mark Woodhall, et al

An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor–positive myasthenia gravis patients

Jose Adolfo Villegas, Jérôme Van Wassenhove, Rozen Le Panse, Sonia Berrih‐Aknin, Nadine Dragin

 

ORIGINAL ARTICLE

Myasthenic syndromes due to defects in COL13A1 and in the Nlinked glycosylation pathway

David Beeson, Judith Cossins, Pedro Rodriguez‐Cruz, Susan Maxwell, Wei‐Wei Liu, Jacqueline Palace


Funding for this publication was made possible (in part) by 1R13NS101926-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.